Phase 1/2Data readout

Zolucatetide (FOG-001) (Beta-Catenin Inhibitor)

Adamantinomatous Craniopharyngioma

PBLSParbaillis Medicines

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Zolucatetide (FOG-001) (Beta-Catenin Inhibitor)
Development stage: Phase 1/2
Event type: Data readout
Indication: Adamantinomatous Craniopharyngioma

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for Zolucatetide (FOG-001) (Beta-Catenin Inhibitor) in Adamantinomatous Craniopharyngioma. The expected timing is based on the latest available company guidance and may change.

Development notes

08/13/26:- Additional ACP clinical data are expected in H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Phase 1/2Data readout

Zolucatetide (FOG-001) (Beta-Catenin Inhibitor)

Adamantinomatous Craniopharyngioma

PBLSParbaillis Medicines

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Zolucatetide (FOG-001) (Beta-Catenin Inhibitor)
Development stage: Phase 1/2
Event type: Data readout
Indication: Adamantinomatous Craniopharyngioma

Research summary

What is being tracked?

Development notes

08/13/26:- Additional ACP clinical data are expected in H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Zolucatetide (FOG-001) (Beta-Catenin Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs